Physician profile
Raza Askari
NPI 1033313671
$4,030.48
in general payments reported to CMS, 2019-2025
28 companies · $964 in 2025
The $964 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $182 · 2021: $239 · 2022: $295 · 2023: $1,152 · 2024: $796 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $847.03 | 2019-2025 | Impella |
| Abbott Laboratories | $599.72 | 2019-2025 | Esprit, Xience Skypoint, Pressurewire |
| Inari Medical, INC. | $545.37 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $286.57 | 2021-2025 | Onyx Frontier, Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $280.83 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $280.14 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $203.08 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $134.13 | 2023-2025 | |
| Ekos Corporation | $101.26 | 2019 | |
| Medtronic Vascular, INC. | $90.62 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $84.96 | 2023-2024 | |
| Philips North America LLC | $79.49 | 2022-2025 | (Ck7) Extended Holter, Extended Holter |
| Merck Sharp & Dohme LLC | $60.54 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $53.97 | 2021-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.05 | 2024 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $39.03 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.21 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $31.60 | 2021-2025 | Lokelma |
| Cvrx, INC. | $28.30 | 2024 | Barostim Neo System |
| Angiodynamics, INC. | $28.26 | 2021-2022 | |
| Bridgebio Pharma, INC. | $27.68 | 2025 | Attruby |
| Bolton Medical INC | $26.84 | 2023 | Treo Abdominal Stent-Graft System |
| Kiniksa Pharmaceuticals International, Plc | $25.93 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $21.97 | 2022 | |
| Surmodics, INC. | $19.06 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.01 | 2025 | Onpattro |
| Akcea Therapeutics, INC. | $17.52 | 2019 | |
| Terumo Medical Corporation | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Askari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.